Ponatinib for CML and Ph+ ALL: five-year results from the PACE trial

Dr. Jorge Cortes on the Phase II Ponatinib PACE TrialПодробнее

Jorge E Cortes, ASCO20: 5-Year Analysis of the Phase II PACE Trial of Ponatinib in Ph+ leukemiaПодробнее

Dose modification of ponatinib in CP-CML: data from the PACE and OPTIC trialsПодробнее

Jorge E Cortes, ASCO20: 5-Year Analysis of the Phase II PACE Trial of Ponatinib in Ph+ leukemiaПодробнее

The recent FDA approval of ponatinib for Ph+ ALL following success in the PhALLCON trialПодробнее

Using ponatinib to treat highly resistant chronic myeloid leukemia, results from a Phase I trialПодробнее

Dr. Cortes on Ponatinib in Patients with CML and Ph+ALLПодробнее

Dr. Jorge Cortes Discusses the Ponatinib Ph+All and CML Evaluation (PACE) TrialПодробнее

Five-year follow-up of OPTIC: ponatinib in CP-CML and its impact on mutational statusПодробнее

Ponatinib + venetoclax for the treatment of R/R Ph+ALLПодробнее

Management of Thrombosis Risk with Ponatinib and other TKIs for CML?Подробнее

PONALFIL trial: ponatinib plus transplant for Ph+ ALLПодробнее

Role of Ponatinib in Treatment of R/R CMLПодробнее

Outcomes of patients with CML-CP treated with ponatinib vs 2G-TKIs in the third-line settingПодробнее

Is Ponatinib Safe for Treating CML?Подробнее

OPTIC: Ponatinib in chronic-phase CMLПодробнее

Ponatinib in chronic-phase CML patients with prior second generation TKI exposureПодробнее

PhALLCON: Phase III study of ponatinib vs imatinib in newly diagnosed Ph+ ALLПодробнее

Interim analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CMLПодробнее